<span item_type="fundamental" item_id="c61b79350944c9fea199fae932f82aea" counter_id="ST/US/HSCS" env="prod"></span><span item_type="announcement" item_id="594032492563007745" env="prod"></span><p>Revenue: As of FY2026 Q2, the actual value is USD 2.419 K.</p><p>EPS: As of FY2026 Q2, the actual value is USD -0.85.</p><p>EBIT: As of FY2026 Q2, the actual value is USD -1.796 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the three months ended October 31, 2025, was $2,419, compared to $0 for the same period in 2024. For the six months ended October 31, 2025, revenue was $4,319, compared to $0 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended October 31, 2025, was - $2,350,769, compared to - $2,082,918 for the same period in 2024. For the six months ended October 31, 2025, the net loss was - $4,405,763, compared to - $4,134,607 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li><li><strong>Gross Margin</strong>: The gross margin for the three months ended October 31, 2025, was $1,411, compared to $0 for the same period in 2024. For the six months ended October 31, 2025, the gross margin was $2,551, compared to $0 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended October 31, 2025, were $2,074,814, compared to $1,985,033 for the same period in 2024. For the six months ended October 31, 2025, operating expenses were $3,950,073, compared to $4,060,700 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended October 31, 2025, net cash used in operating activities was - $4,287,633, compared to - $4,202,270 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the six months ended October 31, 2025, net cash provided by financing activities was $5,157,222, compared to $2,453,417 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Deferred Offering Costs</strong>: As of October 31, 2025, deferred offering costs were $705,499, compared to $290,925 as of April 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: HeartSciences Inc. plans to continue investing in research and development to develop technology for new products, with a focus on obtaining FDA clearance for the MyoVista wavECG device and associated AI-ECG algorithms. The company aims to generate revenue from installation fees, software-as-a-service usage fees, and fees associated with AI-ECG algorithms through the MyoVista Insights platform.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring strategic partnerships and additional equity financing to support its operations and achieve commercialization goals. Management is focused on raising capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468492/000119312525319203/hscs-20251031.htm"></span></li></ul>

HeartSciences | 10-Q: FY2026 Q2 Revenue: USD 2.419 K